SOURCE: The Bedford Report

The Bedford Report

August 18, 2011 08:16 ET

Big Pharma Eyes Speculative Biotech Firms

The Bedford Report Provides Equity Research on MannKind & Celsion

NEW YORK, NY--(Marketwire - Aug 18, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation, and discoveries continue elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on MannKind Corporation (NASDAQ: MNKD) and Celsion Corporation (NASDAQ: CLSN). Access to the full company reports can be found at:

www.bedfordreport.com/MNKD

www.bedfordreport.com/CLSN

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies.

According to Thomson Reuters, on average biotech companies in the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D in 2010, reflecting a 7 percent decline from 2009.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

MannKind's leading drug candidate, Afrezza, is an ultra-rapid acting inhalable insulin that (if approved) will allow diabetes patients to inhale Afrezza before a meal. Last week the company announced that it has confirmed with the US Food and Drug Administration the design of two clinical studies that evaluate the efficacy and safety of Afrezza.

Celsion is an oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. For the second quarter ended June 30, 2011, Celsion reported a net loss of $6.9 million, or $0.42 per share, compared to a net loss of $2.6 million, or $0.22 per share, in the same period of 2010.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information